Chronic respiratory symptoms, von Willebrand factor and longitudinal decline in FEV1

Respiratory Medicine

Volumn 93, Issue 10, 1999, Pages 726-733

  Chambers, D C ^a   Boldy, D A R ^b   Ayres, J G ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b PILGRIM HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHITIS; CIGARETTE SMOKING; CONTROLLED STUDY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MUCUS SECRETION; OBSTRUCTIVE AIRWAY DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SPIROMETRY; WHEEZING;

EID: 0032714513     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90040-9     Document Type: Article

References (31)

1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1997; 1: 1645-1648.
2. Rennard SI. COPD Overview of definitions, epidemiology, and factors influencing its development. Chest 1998; 113: 235S-241S.
3. Anthonisen N. Epidemiology and the lung health study. Eur Respir J 1997; 7: 202-205.
4. Brown CA, Crombie IK, Smith WCS. The impact of quitting smoking on symptoms of chronic bronchitis: results of the Scottish Heart Health Study. Thorax 1991; 46: 112-116.
5. Cullinan P. Persistent cough and phlegm: prevalence and clinical characteristics in south-east England. Respir Med 1992; 86: 143-146.
6. Littlejohns P, Ebrahim S, Anderson R. Prevalence and diagnosis of chronic respiratory symptoms in adults. BMJ 1989; 298: 1556-1560.
7. Strachan DP. Epidemiology: a British perspective. In chronic obstructive pulmonary disease. Calverly P and Pride N Eds. London: Chapman & Hall, 1995: pp. 47-61.
8. Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987; 70(3): 605-611.
9. Kwast TH, Stel HV, Cristen E, Bertina RM, Veerman CI. Localization of factor VIII-procoagulant antigen: an immunohistological survey of the human body using monoclonal antibodies. Blood 1986; 67: 222-227.
10. Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 334: 14-18.
11. Blann AD, Naqvi T, Waite M, McCollum CN. Von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypert 1993; 7: 107-111.
12. Geggel RL, Carvalho CA, Hoyer LW, Reid LM. Von Willebrand factor abnormalities in primary pulmonary hypertension. Am Rev Respir Dis 1987; 135: 294-299.
13. Duffy A, Blann AD, Anderson, J. Miller P, Gowlands E, McCollum CN. Increased von Willebrand factor antigen in familial hypercholesterolaemia with or without vascular disease. Atherosclerosis 1991; 90: 226.
14. Rubin DB, Wiener-Kronish JP, Murray JF et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86: 474-480.
15. Sabharwal AK, Bajaj SP, Ameri A et al. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 1995; 151: 758-767.
16. Jones DK. Markers for impending adult respiratory distress syndrome. Respir Med 1990; 84: 89-91.
17. Boldy DAR, Short PE, Cowen P, Hill FGH, Chambers DC, Ayres JG. Plasma levels of von Willebrand factor antigen in acute bronchitis and in a normal population. Respir Med 1998; 92: 395-400.
18. Burney PGJ, Laitinen LA, Perdrizet S, Huckauf H et al. Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. Eur Respir J 1989; 2: 940-945.
19. Burchfiel CM, Marcus EB, Curb JD et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778-1785.
20. Burrows, B, Lebowitz MD, Camilli AE, Knudson RJ. Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers. Am Rev Respir Dis 1986; 133: 974-980.
21. Ulrik CS, Lange P. Decline of lung function in adults with bronchial asthma. Am J Respir Crit Care Med 1994; 150: 629-634.
22. Short PE, Williams CE, Picken AM, Hill FGH. Factor VIII related antigen: an improved enzyme immunoassay. Med Lab Sci 1982; 39: 351-355.
23. British Thoracic Society & Association of Respiratory Technicians and Physiologists. Topical review. Guidelines for the measurement of respiratory function. Respir Med 1994; 88: 165-194.
24. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax 1996; 51: 164-168.
25. 1 and peripheral blood leukocyte count to total mortality. The normative aging study. Am J Epidemiol 1995; 142: 493-498
26. Bang KM, Gergen PJ, Kramer R, Cohen B. The effect of pulmonary impairment on all-cause mortality in a national cohort. Chest 1993; 103: 536-540.
27. 1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827.
28. Xu X, Laird N, Dockery DW, Schouten JP, Rijcken B, Weiss ST. Age, period, and cohort effects on pulmonary function in a 24-year longitudinal study, Am J Epi 1995; 141: 554-566.
29. Camilli AE, Burrows B, Knudson RJ, Lyle SK, Lebowitz MD. Longitudinal changes in forced expiratory volume in one second in adults. Am Rev Respir Dis 1987; 135: 794-799.
30. Tager IB, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes. Effects of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988; 138: 837-849.
31. Ware JH, Weiss S. Statistical issues in longitudinal research on respiratory health. Am J Respir Crit Care Med 1996; 154: S212-S216.